In the present review, we will discuss the emerging field of vector-mediated antibody gene transfer as an alternative HIV vaccine. This approach is an improvement over classical passive immunization strategies that administer antibodies to the host to provide protection from infection. With vector-mediated gene transfer, the antibody gene is delivered to the host, resulting in long-term endogenous antibody expression from the injected muscle that confers protective immunity.
INTRODUCTION
The need for a safe and effective HIV vaccine is undisputed. In 2012 alone, 1.6 million people died from AIDS-related causes, whereas 2.3 million people were newly infected with HIV [1] . Two HIV-1 Envelope (Env) subunit vaccines tested in phase 3 clinical trials (Vax003 and Vax004) failed to protect vaccine recipients from infection, and neither diminished viral replication after infection [2, 3] . A similar lack of efficacy was also seen from the
Step Study, which used recombinant adenovirus vectors (rAd) that expressed multiple HIV-1 proteins [4, 5] . The RV144 trial in Thailand tested a canary pox vector prime/Env protein boost strategy and showed modest efficacy (31%) [6] . Detailed analyses of the RV144 study results revealed two significant correlations with infection among vaccine recipients. The presence of IgG antibodies against V1V2 Env may have contributed to protection against HIV-1 infection, whereas high levels of Env-specific IgA antibodies correlated inversely with infection [7] . More recently, the HVTN 505 trial was stopped for futility, dealing yet another blow to HIV vaccine efforts [8] . The HVTN 505 trial, which used a DNA prime/rAd boost, showed no difference in HIV-1 infections between those recipients who received the vaccine and those receiving placebo [9] . Vaccine recipients did generate IgG antibodies to Env; however, the majority was nonneutralizing with low reactivity to the V1V2 antigen [9] . These observations underscore the tremendous hurdles that must be overcome to develop an effective HIV vaccine. The foremost problem is figuring out how to induce antibodies that neutralize a wide array of HIV field isolates. Such antibodies are rare, and until recently, only a handful had been isolated and characterized [10] [11] [12] [13] . Over the past few years, more HIV antibodies have been identified that have a much broader range of neutralization and are orders of magnitude more potent than the previously identified group [14 & , [15] [16] [17] [18] [19] [20] [21] . So, what is the best use of the human monoclonals that have been isolated and characterized? Here we will discuss the emerging field of vector-mediated antibody gene transfer, which involves delivering an antibody gene to the target host to endow them with endogenous antibody expression. This strategy is promising in at least three respects. First, gene transfer bypasses the adaptive immune response. Success is not dependent on immunogen design or individual immune responses. Second, one can 'preselect' the anti-HIV transgene(s) of interest. In fact, the door is open to molecules other than antibodies that can be engineered to interfere with HIV entry. Finally, multiple steps in the entry pathway can be targeted. For example, two separate vectors might be designed to block the gp160-CD4 interaction and block viral fusion.
A NEW GENERATION OF BROADLY NEUTRALIZING ANTIBODIES
It was initially believed that potent, broadly neutralizing antibodies (bNAbs) to HIV were extremely rare and difficult to elicit. In fact for some time, only four such antibodies had been identified, known as b12, 2F5, 2G12, and 4E10 [10] [11] [12] [13] . These antibodies provided valuable information as to what regions of HIV envelope were potentially sensitive to neutralization, which could aid in better vaccine antigen design. More recently, a large number of new, significantly more potent bNAbs has been identified using improved screening and sequencing techniques. These newer antibodies were isolated by high-throughput screening of sera from healthy HIV-1-infected individuals categorized as 'elite neutralizers' based on their neutralization breadth and potency [14 & , [15] [16] [17] [18] [19] [20] [21] [22] . Detailed analyses of these antibodies indicated they are approximately 10-100-fold more potent and have an increased breadth compared with the original four isolates. Furthermore, this new class of antibodies can neutralize HIV-1 through binding to a variety of envelope domains, including the CD4 binding site (VRC01, NIH45-46 and PGV04) [17, 20, 23] , glycan containing regions in the variable loops (PG9, PG16, PGT121 and PGT128) [15, 16] , and the membrane-proximal external region (MPER) on gp41 (10E8) [19] .
Epitope mapping of these new, potent antibodies has invigorated the vaccine field by providing precise regions to target when designing new protein or subunit vaccine antigens to induce bNAbs [24] . For example, highly stable Env trimers have been generated that bind to most of the known neutralizing antibodies, but generally do not bind nonneutralizing antibodies, and could potentially be used as a next generation immunogen [25] . However, even with this new wealth of information at hand, generating bNAbs with improved, redesigned antigens may still prove to be problematic. Extensive sequence analysis of these potent bNAbs reveals that high levels of somatic mutations (as much as 30%) can occur in the generation of the mature antibody [15,17,18,20,26 && ]. Furthermore, the maturation may have involved repeated rounds of antibody selection through HIV antigen interaction. In light of this situation, several groups have developed novel immunogens, such as glycopeptides or computation-derived multimerized nanoparticles, which are designed to induce bNAbs [27, 28] . These immunogens can bind to both mature bNAbs and the receptors of their germline (naive) B cells, which can trigger the activation and maturation process required to produce a bNAb.
Although induction of bNAbs by various next generation immunization strategies holds promise, the question remains as to the best use of the human monoclonals that have already been isolated and characterized. One obvious option is passive immunization. Passive immunization using neutralizing monoclonal antibodies has protected monkeys from simian HIV (SHIV) challenge infections [29,30,31,32,33,34,35 && ]. More recently, in the study by Moldt et al. [35 && ], the investigators showed that passively administered PGT121 can mediate sterilizing immunity against SHIV in monkeys at serum concentrations that are significantly lower, suggesting that a protective serum concentration for PGT121 is in the single-digit amount (1.8 mg/ml). Although
KEY POINTS
Vector-mediated antibody gene transfer delivers an antibody gene to the host, resulting in endogenous antibody expression from a single intramuscular injection.
This strategy bypasses the adaptive immune response and allows immediate use of newly isolated potent bNAbs.
Proof-of-concept gene transfer studies in mice and monkeys demonstrate long-term antibody expression and protection from challenge. This strategy can be expanded to include other pathogens that have proven difficult for vaccine development, including hepatitis C virus, influenza, and malaria.
this study demonstrates the potential for passive immunization with the new class of bNAbs, unfortunately, an injection of antibodies every few weeks is not practical or cost-effective as a large-scale human prophylactic vaccine approach.
VECTOR-MEDIATED GENE TRANSFER TO BYPASS ADAPTIVE IMMUNE SYSTEM
Given the difficulties of using the classic concept of passive immunization as a vaccine, we developed a second option: isolate the representative antibody gene and use gene transfer technology to endow a target host with the gene. In this way, the antibody gene directs endogenous expression of the antibody molecule, and the host (in theory) will now have the antibody in its circulation. Our antibody gene delivery vector of choice is the recombinant adenoassociated virus (rAAV) vector, which is derived from wild-type AAV. AAV is Dependovirus with a 4.7 kb single strand DNA genome that contains only two genes (rep and cap) flanked by inverted terminal repeats (ITRs). AAV natural infection is common (approximately 80% of humans are seropositive), and has not been associated with any disease. Multiple AAV serotypes have been identified with different transduction efficiencies in different tissues, offering flexibility for gene transfer targets such as muscle or liver [36] . rAAV vectors have an established record of high-efficiency gene transfer in a variety of model systems [37, 38] . Because of these features, rAAV vectors have become popular gene delivery vehicles for use in clinical studies for the treatment of diseases such as alpha1-antitrypsin deficiency, cystic fibrosis, hemophilia B, Leber's congenital amaurosis, lipoprotein lipase deficiency, Parkinson's disease, and muscular dystrophy [39] .
The rAAV gene transfer vectors are devoid of the endogenous rep and cap genes, and consist of the antibody gene expression cassette flanked by the AAV ITRs. The ITRs (145 bp each), which are necessary for rAAV vector genome replication and packaging, are the only part of the AAV genome present in the rAAV vectors. One method for antibody expression utilizes a two-promoter system, whereby the heavy and light chain genes are transcribed independently using two different promoters and polyadenylation signals within the same rAAV vector genome [40] . Another method uses a single promoter for expression of both the heavy and light chains, which are separated by the foot-and-mouthdisease virus 2A peptide, which undergoes selfcleavage to produce separate heavy and light chain proteins [41] .
Skeletal muscle provides an ideal target for rAAV vector gene transfer. It is easily accessible for injection and can be highly transduced with multiple rAAV serotypes. Following injection, the rAAV vector genome can form stable nonintegrating circular episomes that can persist in nondividing muscle cells [42 & ,43,44] . Thus, after a single injection, the muscle now serves as a depot to synthesize the bNAbs that are passively distributed to the circulatory system (Fig. 1) . The host is now armed with a potent bNAb against HIV-1 that effectively bypasses the adaptive immune system. This is in contrast to the traditional idea of passive immunization, whereby the purified antibodies are injected intravenously into the host to provide protection from infection. However, due to the antibody half-life (approximately 6 days for PGT121 [35 && ]), the levels decline requiring repeated injections. The obvious advantage is that antibody gene transfer engenders the host with long-term antibody persistence from a single injection due to endogenous antibody expression. This methodology need not be confined to HIV; the general strategy of vectormediated antibody gene transfer can be applied to other difficult vaccine targets like hepatitis C virus, malaria, respiratory syncytial virus, and tuberculosis.
ANTIBODY GENE TRANSFER IN VIVO
We first tested the concept of rAAV-mediated antibody gene transfer in animals by using one of the first bNAbs isolated, IgG1b12. The human monoclonal IgG1b12 heavy and light chains were cloned independently into an rAAV genome using the two promoter systems. The resulting vector was injected into the quadriceps muscles of immunodeficient mice (to avoid immune responses to human IgG). IgG1b12 was expressed in mouse muscle (confirmed by histochemical staining), and biologically active antibody was found in sera for over 6 months [40] . Characteristic biologic activity was determined by HIV neutralization assays against IgG1b12-sensitive/resistant viruses. This study provided the first evidence that rAAV vectors transferred antibody genes to muscle; myofibers produced antibodies; antibodies were distributed to the circulation; and such antibodies were biologically active.
Our next objective was to test the gene transfer concept in monkeys in a challenge study. In pilot experiments using the rAAV-IgG1b12 vector, macaques developed antibody responses to the humanderived transgene that effectively shut down expression. To avoid this, we were able to take advantage of native macaque SIV gp120-specific Fab molecular clones that had been derived directly from SIVinfected macaques [45] . When designing the antibody gene transfer vectors, we chose to express the Fabs as immunoadhesins. Immunoadhesins are chimeric, antibody-like molecules that combine the functional domain of a binding protein like a single chain variable fragment or CD4 extracellular domains 1 and 2 (D1D2) with an immunoglobulin constant domain [46] (Fig. 2) , and have been shown to be effective in disease models including HIV, SIV, and influenza [47, 48, 49] . A typical immunoadhesin lacks the constant light chain domain and the constant heavy domain 1 (CH1); however, it can be expressed as a single polypeptide from a single promoter, and forms dimers through disulfide bonding in the hinge region. Furthermore, immunoadhesins may also be secreted from muscle more efficiently than native antibodies, corresponding to higher serum levels (unpublished observation). Although immunoadhesins have many attractive features, they also have some drawbacks. Immunoadhesins may not exhibit the same neutralization breadth and potency as the native antibody. Although we have seen cases in which a specific immunoadhesin functions identically to its native 
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Single injection continuous production FIGURE 1. Immunoprophylaxis by antibody gene transfer. Passive immunization involves intravenous delivery of purified antibodies to engender the host with short-lived immunity in serum and mucosa. In contrast, vector-mediated antibody gene transfer uses a viral vector to deliver the antibody gene to the host via intramuscular injection. The antibody is produced endogenously in the muscle and secreted into the circulatory system and mucosa, providing long-term protection from infection.
antibody counterpart, we have also seen an immunoadhesin become 10-fold less potent at neutralizing HIV-1 (unpublished observation). Thus, immunoadhesins must be fully characterized and compared with the native antibody from which they were derived before consideration as a vaccine. Another drawback to using immunoadhesins is possible immunogenicity. Immunoadhesins are not naturally occurring proteins and may contain amino acid linkers connecting the variable domains (Fig. 2) , which could trigger an immune response, leading to loss of expression.
For the macaque experiments, we constructed two immunoadhesins derived from two different SIV Fab fragments, as well as a third immunoadhesin containing the rhesus CD4 domains 1 and 2 (D1D2), which was modeled after CD4-Ig fusion proteins [50] . All of the constructs neutralized in vitro the proposed SIV challenge stock (SIVmac316), indicating that the immunoadhesins were functioning like the original Fab clones [48] . The three immunoadhesins were injected into three monkeys each (for nine total), followed by an intravenous SIV challenge 4 weeks later, including six naive controls. Immunoadhesin expression levels were as high as 190 mg/ml at the time of challenge (4 weeks postinjection) and peaked around 6 months with levels reaching 400 mg/ml in some animals [48] . Overall, six of the nine monkeys receiving the immunoadhesins were completely protected after challenge, whereas all six naive controls became infected. Analysis of the three monkeys from the immunoadhesin group that became infected revealed that these specific animals had developed an immune response to the immunoadhesin by 3 weeks after injection, suggesting a correlation between an immune response to the immunoadhesin and failure to protect from infection. We have performed longitudinal studies of the protected monkeys, which are now over 6 years postinjection. Immunoadhesin levels dropped to a stable level of approximately 20 mg/ml, which has persisted for over the past 4 years. The monkeys have remained negative for SIV infection and have not developed an immune response to the immunoadhesins (unpublished observation). Thus, this crucial study was instrumental in proving the concept of vectormediated gene transfer as a viable HIV vaccine.
More recently, another group performed rAAV vector-mediated gene transfer expression/challenge studies, which they called vectored immunoprophylaxis [51 && ]. They expressed the native, full antibodies of 2G12, IgG1b12, 2F5, 4E10, and VRC01 using the single promoter foot-and-mouth-disease virus 2A system. Following intramuscular rAAV injection in mice, antibody expression levels greater than 100 mg/ml were observed for at least 12 months. Using a humanized mouse model, they go on to further show that these rAAV vectors can provide protection following HIV challenge, with antibody serum levels as low as 8.3 mg/ml (VRC01). These encouraging results reinforce the efficacy of this approach, especially when potent antibodies such as VRC01 are used. Taken together, these murine and primate studies show that vector-mediated antibody gene transfer can bypass the adaptive immune response and engender the host with antibodies that provide protection from infection. Furthermore, antibody expression can persist several years following a single injection, suggesting long-term protection is possible.
Although antibody gene transfer shows great promise for providing protection from HIV infection, one obvious question is whether this strategy can also be used for antibody therapy in HIVpositive individuals. One study to address this used HIV-infected humanized mice that received an intravenous injection of a rAAV (serotype 8) vector expressing bNAb 10-1074 [52 && ], which targets the base of the V3 stem of gp120 [53] . These mice maintained a high level of antibody 10-1074 expression around 200 mg/ml for the entire length of the 67-day observation period. During this time, six of the seven mice in the group were able to control HIV plasma viral loads, whereas one mouse exhibited viral escape. Future studies administering rAAV vectors simultaneously expressing multiple bNAbs could possibly reduce or even eliminate the generation of escape mutants.
POTENTIAL PITFALLS OF ANTIBODY GENE TRANSFER
Although this approach holds tremendous promise, there are some factors that may limit its effectiveness. Perhaps, the biggest issue is immunogenicity of the antibody; however, this risk is also a concern with passive immunization approaches. At least 22 monoclonal antibodies have been used as therapeutics [54] , and all of these have exhibited some level of immunogenicity [55, 56] . Several factors may contribute to immunogenicity, including structure, dose, and recipient's genetic background. Thus, at this stage, it is difficult to predict which, if any, of the antibodies would be immunogenic, and what the consequences would be. In our nonhuman primate studies [48] , the appearance of antiantibody responses resulted in loss of transgene expression with no adverse events observed. Another concern is the risk that the antibody will bind to an off-target, host protein causing an adverse event, which has been suggested for HIV antibodies 2F5 and 4E10 [57 & ]. One way to predict this occurrence is to do tissue-binding studies with purified proteins, or expression in mouse models [58 & ]. A final point is shutting off antibody expression if an immune response or off-target binding leads to a detrimental effect. Unlike passive immunization, rAAV vectormediated antibody gene transfer results in longterm antibody expression. Thus, if an adverse event were to occur, there is currently no efficient method to eliminate antibody expression.
CONCLUSION
This review highlights the features that make vectormediated antibody gene transfer a novel, unconventional, and innovative approach to the substantial challenge of developing an HIV vaccine. In moving this technology into humans, the first clinical trial using rAAV vector-mediated antibody gene transfer is scheduled to begin in 2014 as a result of collaboration between The Children's Hospital of Philadelphia, The International AIDS Vaccine Initiative, and the Division of AIDS. The rAAV vector will express the PG9 full antibody using the dual promoter system. Although future human trials would utilize even more potent antibodies such as PGT121, the current PG9 study will provide important information about vector safety, antibody concentration, duration of expression, and neutralization capacity. Ultimately, we feel that antibody gene transfer vectors using molecules that inhibit all steps in HIV entry will create a multilayered blockade against HIV infection and provide a shortcut to an HIV vaccine.
